SEC 13F Intelligence

Managers / Q3 2023 · view latest →

CROSSPOINT FINANCIAL, LLC

CIK 0001927769 · 17822 EAST 17TH STREET, SUITE 310, TUSTIN, CA, 92780 · 714-617-4463

Reported Value
$9M
Q3 2023
Positions
9
Filings on Record
13
2019–present window
Filed
Nov 14, 2023
original filing

Summary

Crosspoint Financial, LLC reported $9M in U.S.-listed holdings across 9 positions for Q3 2023.

The portfolio is heavily concentrated: BRK/B alone accounts for 31.9% of reported value.

Compared with Q2 2023, the fund opened 0 new positions and exited 1.

Portfolio Metrics

Turnover
+5.8%
vs prior filed quarter
Largest Position
+31.9%
Berkshire Hathaway

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $9MQ4 ’22Q1 ’23: $9MQ2 ’23: $10MQ2 ’23Q3 ’23: $9MQ4 ’23: $10MQ4 ’23Q1 ’24: $12MQ2 ’24: $24MQ2 ’24Q3 ’24: $29MQ1 ’25: $35MQ1 ’25Q2 ’25: $37MQ4 ’25: $42MQ4 ’25Q1 ’26: $40Mfilingsflow.com

Portfolio Composition

By security type
ETP: 64.3%Common Stock: 35.7%Equity WRT: 0.0%
  • ETP · 64.3% · $6M
  • Common Stock · 35.7% · $3M
  • Equity WRT · 0.0% · $1,950

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TERNS PHARMACEUTICALS INCSOLD OUT12.1K0$105,473$0
ETF SER SOLUTIONSTRIMMED16.3K52.3K$673,151$2M
IAUISHARES GOLD TRTRIMMED2.6K17.4K$120,782$608,549
IHAKISHARES TRADDED+3.8K37.8K+$168,093$1M
OIHVANECK ETF TRUSTHELD+1004.7K+$298,101$2M
BRK/BBERKSHIRE HATHAWAY INC DELHELD+08.6K+$80,030$3M
ALLOALLOGENE THERAPEUTICS INCHELD+012.0K$21,600$38,040
METAMETA PLATFORMS INCHELD+01.1K+$14,355$325,729

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

9 positions
#IssuerClass% PortfolioValueShares
1BRK/BBERKSHIRE HATHAWAY INC DELhistory →CL B NEW31.86%$3M8.6K
2ETF SER SOLUTIONSDEFIANCE NEXT17.29%$2M52.3K
3OIHVANECK ETF TRUSThistory →OIL SERVICES ETF17.10%$2M4.7K
4IHAKISHARES TRhistory →CYBERSECURITY15.38%$1M37.8K
5FIRST TR EXCHNG TRADED FD VIFT CBOE VEST US8.07%$763,53623.1K
6IAUISHARES GOLD TRhistory →ISHARES NEW6.43%$608,54917.4K
7METAMETA PLATFORMS INChistory →CL A3.44%$325,7291.1K
8ALLOALLOGENE THERAPEUTICS INCCOM0.40%$38,04012.0K
9MICROVAST HOLDINGS INC*W EXP 04/01/2020.02%$1,95010.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$40M35May 13, 202613F-HRchanges · EDGAR ↗
Q4 2025$42M37Feb 5, 202613F-HRchanges · EDGAR ↗
Q2 2025$37M33Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$35M30May 1, 202513F-HRchanges · EDGAR ↗
Q3 2024$29M25Oct 18, 202413F-HRchanges · EDGAR ↗
Q2 2024$24M18Jul 26, 202413F-HRchanges · EDGAR ↗
Q1 2024$12M13Apr 24, 202413F-HRchanges · EDGAR ↗
Q4 2023$10M11Feb 7, 202413F-HRchanges · EDGAR ↗
Q3 2023$9M9Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$10M10Aug 10, 202313F-HRchanges · EDGAR ↗
Q1 2023$9M9May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$9M9Feb 8, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.